Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.

Herder C, Illig T, Baumert J, Müller M, Klopp N, Khuseyinova N, Meisinger C, Martin S, Thorand B, Koenig W.

Atherosclerosis. 2008 Oct;200(2):380-8. doi: 10.1016/j.atherosclerosis.2007.12.025. Epub 2008 Feb 1.

PMID:
18242614
2.

Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque.

Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM.

Circulation. 2007 Oct 30;116(18):2043-52. Epub 2007 Oct 15.

3.

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Arthritis Rheum. 2007 Sep;56(9):2905-12.

4.

Systemic inflammation as a risk factor for atherothrombosis.

van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tak PP.

Rheumatology (Oxford). 2008 Jan;47(1):3-7. Epub 2007 Aug 16. Review.

PMID:
17702769
5.

Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.

Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, van der Meer JW, van Riel PL, Stalenhoef AF, Barrera P.

Ann Rheum Dis. 2007 Nov;66(11):1503-7. Epub 2007 May 1.

6.

MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment.

Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, Weber C.

Nat Med. 2007 May;13(5):587-96. Epub 2007 Apr 15.

PMID:
17435771
7.

MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis.

Popa C, van Lieshout AW, Roelofs MF, Geurts-Moespot A, van Riel PL, Calandra T, Sweep FC, Radstake TR.

Cytokine. 2006 Oct;36(1-2):51-6. Epub 2006 Dec 12.

PMID:
17166737
8.

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.

Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P.

Ann Rheum Dis. 2007 May;66(5):670-5. Epub 2006 Dec 11.

9.
10.

MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis.

Morand EF, Leech M, Bernhagen J.

Nat Rev Drug Discov. 2006 May;5(5):399-410. Review.

PMID:
16628200
11.

Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB.

Amin MA, Haas CS, Zhu K, Mansfield PJ, Kim MJ, Lackowski NP, Koch AE.

Blood. 2006 Mar 15;107(6):2252-61. Epub 2005 Nov 29.

12.

Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor.

Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, Calandra T, Donn R, van Riel PL.

Arthritis Rheum. 2005 Oct;52(10):3020-9.

13.

Anti-TNF therapy and plasma HDL cholesterol concentration.

Popa C, Barrea P, Netea MG, Stalenhoef AF, van der Meer JW.

Atherosclerosis. 2005 Oct;182(2):375; author reply 377. No abstract available.

PMID:
15998519
14.

Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.

Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA.

Ann Rheum Dis. 2005 May;64(5):765-6. Epub 2004 Sep 30.

15.

Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice.

Gregory JL, Leech MT, David JR, Yang YH, Dacumos A, Hickey MJ.

Arthritis Rheum. 2004 Sep;50(9):3023-34.

16.
17.

Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice.

Brånén L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S.

Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2137-42. Epub 2004 Sep 2.

18.

Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice.

Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, Weber C.

Circulation. 2004 Jan 27;109(3):380-5. Epub 2003 Dec 22.

19.

Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis.

Sattar N, McCarey DW, Capell H, McInnes IB.

Circulation. 2003 Dec 16;108(24):2957-63. Review.

Supplemental Content

Support Center